You are here

Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
MGH Neuropathy Laboratory
Boston, Massachusetts, 02114 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Familial Amyloid Polyneuropathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Amyloid documented by biopsy.

2. Documented V30M TTR mutation.

3. Peripheral and/or autonomic neuropathy with a Karnofsky Performance Status ≥50.

4. Patient is 18-75 years old.

5. If female, patient is post-menopausal, surgically sterilized, or willing to use an
acceptable method of birth control. If male with a female partner of childbearing
potential, willing to use an acceptable method of birth control for the duration of
the study. For both females and males, birth control must be used for at least 3
months after the last dose of study medication.

6. Patient is, in the opinion of the investigator, willing and able to comply with the
study medication regimen and all other study requirements.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs).

2. Primary amyloidosis.

3. If female, patient is pregnant or breast feeding.

4. Prior liver transplantation.

5. No recordable sensory threshold for vibration perception in both feet, as measured by
CASE IV.

6. Positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus
(HCV), and/or human immunodeficiency virus (HIV).

7. Renal insufficiency or liver function test abnormalities.

8. New York Heart Association (NYHA) Functional Classification ?III.

9. Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV
treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic
inflammatory diseases).

10. Co-morbidity anticipated to limit survival to less than 18 months.

11. Patient received an investigational drug/device and/or participated in another
clinical investigational study within 60 days before Baseline.

NCT00409175
Pfizer
Completed
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Transthyretin Mutations, Transthyretin Amyloidosis
NCT00628745
All Genders
18+
Years
Multiple Sites
Familial Persistent Pulmonary Hypertension
NCT01720524
All Genders
0+
Years
Multiple Sites
Familial Hypercholesterolemia
NCT00134511
All Genders
18+
Years
Multiple Sites
Familial Hypercholesterolemia, Hyperlipidemia
NCT00134485
All Genders
18+
Years
Multiple Sites
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study

This study will examine whether Fx-1006A is effective in halting the progression of Familial Amyloid Polyneuropathy (FAP).

Deposition of TTR amyloid is associated with a variety of human diseases. Deposition of amyloid fibrils of variant TTR (primarily V30M) in peripheral nerve tissue produces the condition called FAP.

The prevention of the formation of amyloid by stabilization of the TTR native state should constitute an effective therapy for amyloid diseases. Therapeutic intervention with a TTR stabilizer drug, such as Fx-1006A, is hypothesized to stop progression of the disease in FAP patients. FAP is a uniformly fatal disease and Fx-1006A is intended to halt the relentless neurological deterioration FAP patients experience.

This Phase 2/3 study will enroll early to mid-stage FAP patients in order to interrupt and stabilize the disease at a point in time where progression of motor and autonomic dysfunction can be maximally effected. Male and female patients with FAP with documented V30M TTR mutation will receive Fx-1006A or placebo once daily for a period of eighteen (18) months.

Deposition of TTR amyloid is associated with a variety of human diseases. Deposition of amyloid fibrils of variant TTR (primarily V30M) in peripheral nerve tissue produces the condition called FAP.

The prevention of the formation of amyloid by stabilization of the TTR native state should constitute an effective therapy for amyloid diseases. Therapeutic intervention with a TTR stabilizer drug, such as Fx-1006A, is hypothesized to stop progression of the disease in FAP patients. FAP is a uniformly fatal disease and Fx-1006A is intended to halt the relentless neurological deterioration FAP patients experience.

This Phase 2/3 study will enroll early to mid-stage FAP patients in order to interrupt and stabilize the disease at a point in time where progression of motor and autonomic dysfunction can be maximally effected. Male and female patients with FAP with documented V30M TTR mutation will receive Fx-1006A or placebo once daily for a period of eighteen (18) months.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Familial Amyloid Polyneuropathy
  • Drug: Fx-1006A
    Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
  • Drug: Placebo
    Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
  • Experimental: 1.
    Fx-1006A
    Intervention: Drug: Fx-1006A
  • Placebo Comparator: 2.
    Placebo
    Intervention: Drug: Placebo
Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016 Sep;23(3):178-183. Epub 2016 Aug 5.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
128
May 2009
May 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Amyloid documented by biopsy.
  2. Documented V30M TTR mutation.
  3. Peripheral and/or autonomic neuropathy with a Karnofsky Performance Status ?50.
  4. Patient is 18-75 years old.
  5. If female, patient is post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control. If male with a female partner of childbearing potential, willing to use an acceptable method of birth control for the duration of the study. For both females and males, birth control must be used for at least 3 months after the last dose of study medication.
  6. Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements.

Exclusion Criteria:

  1. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs).
  2. Primary amyloidosis.
  3. If female, patient is pregnant or breast feeding.
  4. Prior liver transplantation.
  5. No recordable sensory threshold for vibration perception in both feet, as measured by CASE IV.
  6. Positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV).
  7. Renal insufficiency or liver function test abnormalities.
  8. New York Heart Association (NYHA) Functional Classification ?III.
  9. Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic inflammatory diseases).
  10. Co-morbidity anticipated to limit survival to less than 18 months.
  11. Patient received an investigational drug/device and/or participated in another clinical investigational study within 60 days before Baseline.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Brazil,   France,   Germany,   Portugal,   Spain,   Sweden,   United Kingdom,   United States
 
 
NCT00409175
FX-005
B3461020
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Jeff Packman FoldRx Pharmaceuticals, Inc.
Pfizer
November 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now